AUROBINDO PHARMA

Company History

Aurobindo Pharma was born of a vision. Founded in 1986 by Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals, the company became a public venture in 1992. It commenced operations in 1988-89 with a single unit manufacturing semi synthetic penicillins (SSPs) at Pondicherry.

Aurobindo Pharma had gone public in 1995 by listing its shares in various stock exchanges in the country. The company is the market leader in semi-synthetic penicillin drugs. It has a presence in key therapeutic segments like SSPs, cephalosporins, antivirals, CNS, cardio-vascular, gastroenterology, etc.

Over the years, the Aurobindo Pharma has evolved into a knowledge driven company. It is R&D focused, has a multi-product portfolio with multi-country manufacturing facilities, and is becoming a marketing conglomerate across the world.

Aurobindo Pharma created a name for itself in the manufacture of bulk actives, its area of core competence. After ensuring a firm foundation of cost effective production capabilities and a clutch of loyal customers, the company has entered the high margin speciality generic formulations segment, with a global marketing network.

The formulation business is systematically organised with a divisional structure, and has a focused team for each key international market. Aurobindo believes in gaining volume and market share in every business/segment it enters.

Aurobindo has invested significant resources in building a mega infrastructure for APIs and formulations to emerge as a vertically integrated pharmaceutical company. Aurobindo’s five units for APIs and four units for formulations are designed for the regulated markets.

Board of Directors Mr. P.V.Ramaprasad Reddy, (50) Chairman Mr. K.Nityananda Reddy, (50) Managing Director Mr. M. Madan Mohan Reddy, (48) Whole-time Director Dr. M.Sivakumaran, (65) Whole-time Director Mr. M.Sitarama Murthy, (64) Non-Executive Director Dr.P.L.Sanjeev Reddy, (68) Non-Executive Director Dr. D. Rajagopala Redddy, (50) Non-Executive Director Dr. K. Ramachandran, (52) Non-Executive Director Mr.K.Ragunathan, (45) Non-Executive Director Mr.P.Sarath Chandra Reddy, (23) Business Strategy The robustness of business strategies are reviewed by the management at regular intervals. The business plans are modified and improvements made as an ongoing process. The medium term strategy of Aurobindo Pharma is to continuously globalise the intellectual property assets and enhance value to shareholders and customers. In global markets, the Company shall retain and enhance cost efficient quality leadership in semi synthetic penicillins, cephalosporins, newer anti infectives and lifestyle disease drugs. It is the endeavour of the Company to achieve this by resolving complex chemistry challenges, improving process efficiencies, adopting global scale manufacturing and using cost effective market networks throughout South East Asia, Africa and Latin America. Aurobindo Pharma shall repeat its success and emerge as a major player in regulated markets. The Company will obtain regulatory approvals by filing Drug Master Files (DMF) and Abbreviated New Drug Applications (ANDA) in lifestyle disease drugs and sterile and non-sterile cephalosporins having substantial entry barriers. The Company’s competitive advantage is in capturing a large portfolio of approvals, backed up by a global standard R&D effort that offers several patented non-infringing processes and intellectual properties, and a cost efficient mega manufacturing environment complying to US FDA and EU authorities. The Company shall forge alliances with original research companies in the area of custom synthesis. The existing relationships and credibility will help Aurobindo Pharma to acquire a significant part of bulk manufacturing of original research companies into its units. The corporate plans are to ensure growth through organic means, and by adopting strategic joint ventures and alliances. The objective is to maximize the revenues and reduce risks.

AVON ORGANICS -The only diketene manufacturer

It is said that for a commendable success story, the interest should lie in the future, as that is where one spends most of the time. A keen insight and a well-planned development process saw AOL discover the opportunity in the production of Diketene - the basic unit for hundreds of derivatives in pesticides, chemicals, pharmaceuticals and dyestuffs. A highly classified technology, it has been sourced from Shanghai Peng Pu Chemical Works, China, and Xytel Technology Partnership, USA, and now rests in the hands of a few chosen manufacturers across the globe.
FACILITY
The company, with its immense infrastructure framework has introduced modifications to the Chinese technology and has a current production of 3000 tonnes per annum against an installed capacity of 2000 tonnes per annum. A sprawling facility of 21 acres, the plant is situated 60 kilometres from Hyderabad. The locale is ideal due to its easy connectivity made possible by the well-traversed National Highway # 9 that links Hyderabad with Mumbai.

HISTORY

Being in the business of manufacturing machinery for chemical, bulk drug and resin plants proved to be a head start to two visionary entrepreneurs who shared the dream of constructing and operating their own high-tech chemical plant. The two entrepreneurs, Mr. P R Agarwal, Mr. Rajesh Agarwal along with late Dr G S Sidhu, 'combined' their strengths to set up Avon Organics Limited (AOL) with an objective to serve worldwide markets with high value-added industrial products for the pharmaceuticals, agro and dyestuff & pigment industries. The company's main focus is on producing fine chemicals for these industries.
The transition from a machinery manufacturer to a full-fledged chemical manufacturer saw the company foraying into the highly technology-intensive area of Diketene and its derivatives. Hence began an era of excellence beyond compare in the manufacture of chemicals as initiated and benchmarked by AOL.The year 1996 saw the establishment and successful commissioning of AOL's first grass root Diketene plant. Diligently run and controlled by a dedicated 300-strong team comprising of managers, engineers, chemists, supervisors and workmen, each hand-picked for their expertise, the plant has been garnering accolades and achievements on a regular basis.The company's growth pinnacled when it doubled its production capacity by commissioning an additional 1000 TPA unit as part of its second phase in 1998.
Hyderabad, a city where the chemical industry has carved a comfortable niche for itself, was the unanimous choice of the promoters to locate the company. A prominent marquee among the prominent "Profit Making Companies" in India, AOL has been on a steady and unabated upward journey. Uncompromising quality standards, intelligent innovations that redefine manufacturing and a commitment to the customer needs has been their mantra for success. An ISO 9000 certification by the Lloyds Register Quality Assurance (LRQA) highlighted the company's quality standards and instills a deserving sense of confidence in the elaborate quality control procedures followed in the plant.
for more details visit
http://www.avonorganicsltd.com/

Cipla -The indian pharma major

Cipla is born
In 1935, he set up The Chemical, Industrial & Pharmaceutical Laboratories, which came to be popularly known as Cipla. He gave the company all his patent and proprietary formulas for several drugs and medicines, without charging any royalty. On August 17, 1935, Cipla was registered as a public limited company with an authorised capital of Rs 6 lakhs.
The search for suitable premises ended at 289, Bellasis Road (the present corporate office) where a small bungalow with a few rooms was taken on lease for 20 years for Rs 350 a month.
Cipla was officially opened on September 22, 1937 when the first products were ready for the market. The Sunday Standard wrote: "The birth of Cipla which was launched into the world by Dr K A Hamied will be a red letter day in the annals of Bombay Industries. The first city in India can now boast of a concern, which will supersede all existing firms in the magnitude of its operations. India has lagged behind in the march of science but she is now awakening from her lethargy. The new company has mapped out an ambitious programme and with intelligent direction and skillful production bids fair to establish a great reputation in the East. "

Milestones
1935
Dr K A Hamied sets up "The Chemical, Industrial and Pharmaceutical Laboratories Ltd." in a rented bungalow, at Bombay Central.

1941
As the Second World War cuts off drug supplies, the company starts producing fine chemicals, dedicating all its facilities for the war effort.

1952
Sets up first research division for attaining self-sufficiency in technological development.

1960
Starts operations at second plant at Vikhroli, Mumbai, producing fine chemicals with special emphasis on natural products.

1968
Cipla manufactures ampicillin for the first time in the country.

1972
Starts Agricultural Research Division at Bangalore, for scientific cultivation of medicinal plants.

1976
Cipla launches medicinal aerosols for asthma.

1980
Wins Chemexcil Award for Excellence for exports.

1982
Fourth factory begins operations at Patalganga, Maharashtra.

1984
Develops anti-cancer drugs, vinblastine and vincristine in collaboration with the National Chemical Laboratory, Pune. Wins Sir P C Ray Award for developing inhouse technology for indigenous manufacture of a number of basic drugs.

1985
US FDA approves Cipla's bulk drug manufacturing facilities.

1988
Cipla wins National Award for Successful Commercialisation of Publicly Funded R&D.

1991
Lauches etoposide, a breakthrough in cancer chemotherapy, in association with Indian Institute of Chemical Technology.
The company pioneers the manufacture of the antiretroviral drug, zidovudine, in technological collaboration with Indian Institute of Chemical Technology, Hyderabad.

1994
Cipla's fifth factory begins commercial production at Kurkumbh, Maharashtra.

1997
Launches transparent Rotahaler, the world's first such dry powder inhaler device now patented by Cipla in India and abroad. The palliative cancer care centre set up by the Cipla Foundation, begins offering free services at Warje, near Pune.

1998
Launches lamivudine, becoming one of the few companies in the world to offer all three component drugs of retroviral combination therapy (zidovudine and stavudine already launched).

1999
Launches Nevirapine, antiretroviral drug, used to prevent the transmission of AIDS from mother to child.

2000
Cipla became the first company, outside the USA and Europe to launch CFC-free inhalers – ten years before the deadline to phase out use of CFC in medicinal products.

2002
Four state-of-the-art manufacturing facilities set up in Goa in a record time of less than twelve months.

2003
Launches TIOVA (Tiotropium bromide), a novel inhaled, long-acting anticholinergic bronchodilator that is employed as a once-daily maintenance treatment for patients with chronic obstructive pulmonary disease (COPD).
Commissioned second phase of manufacturing operations at Goa.

2005
Set-up state-of-the-art facility for manufacture of formulations at Baddi, Himachal Pradesh.

2007
Set-up state-of-the-art facility for manufacture of formulations at Sikkim.